RenovoRx, Inc. (NASDAQ:RNXT – Free Report) – Investment analysts at HC Wainwright raised their Q2 2026 earnings per share (EPS) estimates for shares of RenovoRx in a research report issued to clients and investors on Friday, May 15th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of ($0.08) for the quarter, up from their previous estimate of ($0.09). HC Wainwright currently has a “Buy” rating and a $3.00 price target on the stock. The consensus estimate for RenovoRx’s current full-year earnings is ($0.31) per share. HC Wainwright also issued estimates for RenovoRx’s Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.33) EPS, Q1 2027 earnings at ($0.03) EPS, Q2 2027 earnings at ($0.02) EPS, Q3 2027 earnings at $0.00 EPS, Q4 2027 earnings at $0.01 EPS, FY2027 earnings at ($0.02) EPS and FY2028 earnings at $0.20 EPS.
RenovoRx (NASDAQ:RNXT – Get Free Report) last announced its earnings results on Thursday, May 14th. The company reported ($0.08) EPS for the quarter, meeting the consensus estimate of ($0.08). The business had revenue of $0.56 million for the quarter, compared to the consensus estimate of $0.47 million. RenovoRx had a negative return on equity of 135.03% and a negative net margin of 823.98%.
View Our Latest Research Report on RenovoRx
RenovoRx Stock Performance
Shares of NASDAQ:RNXT opened at $0.78 on Tuesday. The company has a market cap of $35.29 million, a P/E ratio of -2.37 and a beta of 1.00. RenovoRx has a one year low of $0.70 and a one year high of $1.45. The business’s 50-day simple moving average is $0.94 and its 200 day simple moving average is $0.94.
Institutional Investors Weigh In On RenovoRx
Several hedge funds and other institutional investors have recently bought and sold shares of RNXT. AIGH Capital Management LLC increased its holdings in RenovoRx by 30.8% during the 1st quarter. AIGH Capital Management LLC now owns 3,706,197 shares of the company’s stock worth $3,682,000 after purchasing an additional 872,303 shares during the last quarter. Wealthspire Advisors LLC purchased a new stake in RenovoRx during the 4th quarter worth approximately $212,000. Citadel Advisors LLC purchased a new stake in RenovoRx during the 3rd quarter worth approximately $154,000. Northwestern Mutual Wealth Management Co. purchased a new stake in RenovoRx during the 2nd quarter worth approximately $98,000. Finally, Bleichroeder LP increased its holdings in RenovoRx by 11.4% during the 4th quarter. Bleichroeder LP now owns 600,000 shares of the company’s stock worth $504,000 after purchasing an additional 61,379 shares during the last quarter. 3.10% of the stock is currently owned by hedge funds and other institutional investors.
About RenovoRx
RenovoRx, Inc is a clinical-stage medical technology company focused on the development of proprietary drug-device combination therapies for the treatment of solid tumor malignancies. The company’s lead product candidate, RenovoCath™, is an intra-arterial catheter system designed to deliver high concentrations of chemotherapeutic agents directly to tumor sites while minimizing systemic exposure. RenovoRx seeks to improve clinical outcomes and reduce adverse effects by enhancing drug delivery precision in hard-to-treat cancers.
RenovoCath™ is being evaluated in multiple clinical trials targeting advanced pancreatic cancer and metastatic colorectal cancer, among other solid tumors.
See Also
- Five stocks we like better than RenovoRx
- Why Trump’s Amazon Stock Sale May Not Matter at All
- Why Applied Optoelectronics Stock May Be Near a Turning Point
- From High-Yield to High-Growth: 3 Stocks Boosting Dividends
- Is Everspin Technologies the Next AI Edge Breakout?
Receive News & Ratings for RenovoRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RenovoRx and related companies with MarketBeat.com's FREE daily email newsletter.
